[1]刘李平,宋徽,冀垒兵,等.玻璃体内注射雷珠单抗治疗病理性近视黄斑部脉络膜新生血管[J].眼科新进展,2016,36(7):667-670.[doi:10.13389/j.cnki.rao.2016.0177]
　LIU Li-Ping,SONG Hui,JI Lei-Bing,et al.Intravitreal ranibizumab injections for pathologic myopia macular choroidal neovascularization[J].Recent Advances in Ophthalmology,2016,36(7):667-670.[doi:10.13389/j.cnki.rao.2016.0177]
点击复制

玻璃体内注射雷珠单抗治疗病理性近视黄斑部脉络膜新生血管
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
36卷
期数:
2016年7期
页码:
667-670
栏目:
应用研究
出版日期:
2016-07-05

文章信息/Info

Title:
Intravitreal ranibizumab injections for pathologic myopia macular choroidal neovascularization
作者:
刘李平; 宋徽; 冀垒兵; 肖云; 李明; 陈珍
830013　新疆乌鲁木齐市，解放军第４７４医院眼科医院，全军眼科中心（刘李平，冀垒兵，肖云，李明，陈珍）；100089　北京市，解放军第３０９医院眼科（宋徽）
Author(s):
LIU Li-Ping; SONG Hui ; JI Lei-Bing ; XIAO Yun ;  LI Ming; CHEN Zhen
Department of Ophthalmology , the 474th Hospital of PLA ( LIU Li-Ping, JI Lei-Bing, XIAO Yun, LI Ming , CHEN Zhen ) . Urumqi 830013 , Xinjiang Uyghur Autonomous Region , China ; Department of Ophthalmology , the 309th Hospital of PLA ( SONG Hui ) ,Beijing 100089 , China
关键词:
脉络膜新生血管; 病理性近视; 血管内皮生长因子; 雷珠单抗
Keywords:
choroidal neovascularization;  pathologic myopia;  vascular endothelial growth factor ;  anti-vascular endothelial growth factor ;  ranibizumab
分类号:
Ｒ７７４.５
DOI:
10.13389/j.cnki.rao.2016.0177
文献标志码:
A
摘要:
目的　评估玻璃体内注射雷珠单抗治疗病理性近视黄斑部脉络膜新生血管的临床疗效及安全性。方法　选择我院门诊于２０１２年１１月至２０１５年５月明确诊断为高度近视性黄斑部脉络膜新生血管患者５６例５６眼，视治疗情况给予玻璃体内注射单次或多次雷珠单抗，注射后随访６个月，记录最佳矫正视力（ｂｅｓｔｃｏｒｒｅｃｔｅｄｖｉｓｕａｌａｃｕｉ-ｔｙ，ＢＣＶＡ）及光学相干断层扫描和眼底荧光血管造影结果。结果　治疗过程中，行一次注射者１７例１７眼，两次者３２例３２眼，三次者７例７眼，平均注射１．８２次。治疗后ＢＣＶＡ为０．３１±０．３６，较治疗前的０．０８±０．２６明显提高（Ｐ＜０．０５），视力提高及稳定者占８７．３％。年龄≥５０岁者１６例１６眼，治疗前ＢＣＶＡ为０．０４±０．３８，治疗后为０．２５±０．３１（ｔ＝２．２３８，Ｐ＜０．０５）；年龄＜５０岁者４０例４０眼，治疗前ＢＣＶＡ为０．１８±０．３２，治疗后为０．５４±０．３３（ｔ＝３．３４１，Ｐ＜０．０５）；脉络膜新生血管位于中心凹下者１９例１９眼，治疗前ＢＣＶＡ为０．０５±０．２６，治疗后为０．２９±０．３７（ｔ＝２．３１９，Ｐ＜０．０５），位于中心凹旁者３７例３７眼，治疗前ＢＣＶＡ为０．２１±０．２７，治疗后为０．５６±０．３１（ｔ＝２．９８１，Ｐ＜０．０５）。光学相干断层扫描示黄斑部视网膜厚度治疗前为（３６５．１３±９８．７７）μｍ，治疗后为（２５４．２４±５４．８６）μｍ（ｔ＝３．１６４，Ｐ＜０．０５）。ＦＦＡ检查黄斑部ＣＮＶ荧光渗漏消失者４９例４９眼；黄斑部脉络膜新生血管渗漏持续存在，但较治疗前渗漏面积明显减弱者７例７眼。结论　玻璃体内注射雷珠单抗治疗病理性近视黄斑部脉络膜新生血管安全、有效。
Abstract:
Objective To evaluate the clinical effects and safety of intravitreal injection of aanibizumab for macular choroidal neovascularization secondary to pathologic myopia. Methods Fifty-six eyes of 66 cases diagnosed as macular choroidal neovascularization secondary to pathologic myopia definitely were intravitreally injected Ranibizumab from November 2012 to May 2015 with one to three times . the changes of the best corrected visual activity , slit lamp examination , funduscopes examination . fluorescein fundus angiography test and optical coherence tomography test before and 6 months after treatment were observed. Results During the treatment . 17 eyes ,32 eyes and 7 eyes were injected once .twice and three times ,respectively. Best corrected visual activity were 0. 08 +0. 26 and 0. 31 + 0. 36 before and after treatment . the visual activity improved obviously comparing to pre-therapy ( P < 0. 05 ) . Age more than 50 years old were in 16 eyes, the visual acuity were 0. 04 + 0. 38 and 0. 25 + 0. 31 , respectively, the difference was significant ( t = 2. 238 ,P < 0. 05 ) . Age less than 50 years old were in 40 eyes ,the visual acuity were 0. 18 +0. 32 and 0. 54 +0. 33 before and after treatment , respectively , the difference was significant ( t = 3. 341 ,P < 0. 05 ) . Choroidal neovascularization in subfovea were in 19 eyes , the visual acuity were 0. 05 +0. 26 and 0. 29 +0. 37 before and after treatment, respectively, the difference was sigruficant ( t = 2. 319, P < 0. 05 ) ; And located in parafovea were in 37 eyes.the visual acuity were 0. 21 +0. 27 and 0. 56 + 0. 31 before and after treatment, respectively , the difference was sigruficant ( t = 2. 981 .P <0. 05 ). Central retinal thickness were ( 365. 13 + 98. 77) Vm and ( 254. 24 + 54. 86 ) ym before and after therapy , the difference was significant ( P < 0. 05 ) . Leakage of retina disappeared in 49 eyes , alleviated obviously in 7 eyes. Conclusion Intravitreal injection of ranibizumab for macular choroidal neovascularization secondary to pathologic myopia is effective and safe.

相似文献/References:

[1]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[2]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[3]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[4]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[5]陈丽娟 苗林.重组人血管内皮抑素对脉络膜新生血管的抑制作用[J].眼科新进展,2012,32(10):000.
[6]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[7]常远 王雨生 曹丰 张健 蔡岩 李鹤一 侯慧媛.在体生物发光成像术观察骨髓来源细胞参与脉络膜新生血管的形成[J].眼科新进展,2013,33(5):000.
[8]雷润佳 胡丹 张鹏 孙丽娟 白倩 闵捷.缺氧对人视网膜色素上皮细胞促血管生成素-1和促血管生成素-2表达的影响[J].眼科新进展,2013,33(5):000.
[9]王晓霞 史志洁 林娜 刘晓瑞.光学相干断层扫描在病理性近视黄斑裂孔中的应用[J].眼科新进展,2013,33(9):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[12]黄志坚 宋艳萍 金中秋 丁琴 陈中山.光动力疗法联合玻璃体内注射Bevacizumab治疗病理性近视合并脉络膜新生血管[J].眼科新进展,2013,33(4):000.
[13]陆秉文,吴星伟. Ranibizumab玻璃体内注射治疗病理性近视脉络膜新生血管研究进展[J].眼科新进展,2014,34(9):897.[doi:10.13389/j.cnki.rao.2014.0248]
[14]丁雯芝,邹俊.病理性近视脉络膜新生血管发病机制的研究进展[J].眼科新进展,2014,34(10):987.[doi:10.13389/j.cnki.rao.2014.0274]
[15]田楠楠,亢泽峰,张庆.加减驻景方对病理性近视脉络膜新生血管动物模型血管内皮生长因子及色素上皮衍生因子表达的影响[J].眼科新进展,2015,35(10):906.[doi:10.13389/j.cnki.rao.2015.0247]
　TIAN Nan-Nan,KANG Ze-Feng,ZHANG Qing.Effects of modified Zhu Jing prescriptions on expression of VEGF and PEDF in pathologic myopia with choroidal neovascularization animal model[J].Recent Advances in Ophthalmology,2015,35(7):906.[doi:10.13389/j.cnki.rao.2015.0247]
[16]修立恒,李佳林,李常栋,等.玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察[J].眼科新进展,2015,35(11):1067.[doi:10.13389/j.cnki.rao.2015.0292]
　XIU Li-Heng,LI Jia-Lin,LI Chang-Dong,et al.Pathological myopia combined with choroidal neovascularization treated by intravitreal injection of ranibizumab[J].Recent Advances in Ophthalmology,2015,35(7):1067.[doi:10.13389/j.cnki.rao.2015.0292]
[17]孙早荷,万光明,钱诚,等.玻璃体内注射雷珠单抗治疗病理性近视继发脉络膜新生血管[J].眼科新进展,2018,38(10):925.[doi:10.13389/j.cnki.rao.2018.0219]
　SUN Zao-He,WAN Guang-Ming,QIAN Cheng,et al.Efficacy of intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to pathological myopia[J].Recent Advances in Ophthalmology,2018,38(7):925.[doi:10.13389/j.cnki.rao.2018.0219]
[18]陈丛,闫明,宋艳萍.康柏西普对病理性近视脉络膜新生血管的疗效及视力预后相关性研究[J].眼科新进展,2020,40(6):569.[doi:10.13389/j.cnki.rao.2020.0131]
　CHEN Cong,YAN Ming,SONG Yanping.Efficacy of Conbercept for treatment of choroidal neovascularization with pathologic myopia and on visual prognosis[J].Recent Advances in Ophthalmology,2020,40(7):569.[doi:10.13389/j.cnki.rao.2020.0131]
[19]叶蓉,张秋阳,张荟颖,等.不同类型脉络膜新生血管患者对抗VEGF药物治疗应答的差异性[J].眼科新进展,2022,42(12):952.[doi:10.13389/j.cnki.rao.2022.0195]
　YE Rong,ZHANG Qiuyang,ZHANG Huiying,et al.Differences in responses to anti-vascular endothelial growth factor drugs of patients with different types of choroidal neovascularization[J].Recent Advances in Ophthalmology,2022,42(7):952.[doi:10.13389/j.cnki.rao.2022.0195]

更新日期/Last Update: 2016-07-12